CN114126655A - 用利匹韦林治疗儿科患者的hiv的方法 - Google Patents

用利匹韦林治疗儿科患者的hiv的方法 Download PDF

Info

Publication number
CN114126655A
CN114126655A CN202080048751.4A CN202080048751A CN114126655A CN 114126655 A CN114126655 A CN 114126655A CN 202080048751 A CN202080048751 A CN 202080048751A CN 114126655 A CN114126655 A CN 114126655A
Authority
CN
China
Prior art keywords
rilpivirine
pharmaceutically acceptable
acceptable salt
subject
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080048751.4A
Other languages
English (en)
Chinese (zh)
Inventor
H·克劳威尔斯
S·范维尔格
V·范艾根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Original Assignee
Janssen R&D Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland ULC filed Critical Janssen R&D Ireland ULC
Publication of CN114126655A publication Critical patent/CN114126655A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080048751.4A 2019-07-03 2020-07-02 用利匹韦林治疗儿科患者的hiv的方法 Pending CN114126655A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
US62/870413 2019-07-03
PCT/EP2020/068734 WO2021001508A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv in pediatric patients with rilpivirine

Publications (1)

Publication Number Publication Date
CN114126655A true CN114126655A (zh) 2022-03-01

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080048751.4A Pending CN114126655A (zh) 2019-07-03 2020-07-02 用利匹韦林治疗儿科患者的hiv的方法
CN202080048752.9A Pending CN114080223A (zh) 2019-07-03 2020-07-03 用利匹韦林治疗儿科患者的hiv的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080048752.9A Pending CN114080223A (zh) 2019-07-03 2020-07-03 用利匹韦林治疗儿科患者的hiv的方法

Country Status (14)

Country Link
US (3) US20210000823A1 (cg-RX-API-DMAC7.html)
EP (2) EP3993799A1 (cg-RX-API-DMAC7.html)
JP (4) JP2022538338A (cg-RX-API-DMAC7.html)
KR (2) KR20220028049A (cg-RX-API-DMAC7.html)
CN (2) CN114126655A (cg-RX-API-DMAC7.html)
AU (2) AU2020300818A1 (cg-RX-API-DMAC7.html)
BR (2) BR112021026916A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144307A1 (cg-RX-API-DMAC7.html)
IL (1) IL289457A (cg-RX-API-DMAC7.html)
JO (1) JOP20210347A1 (cg-RX-API-DMAC7.html)
MA (2) MA56449A (cg-RX-API-DMAC7.html)
MX (2) MX2022000060A (cg-RX-API-DMAC7.html)
PH (1) PH12021553288A1 (cg-RX-API-DMAC7.html)
WO (2) WO2021001508A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103491948A (zh) * 2010-11-19 2014-01-01 吉里德科学公司 包含利匹韦林hci和富马酸替诺福韦酯的治疗组合物
CN107921003A (zh) * 2015-06-30 2018-04-17 吉利德科学公司 药物制剂
WO2019003150A2 (en) * 2017-06-30 2019-01-03 Viiv Healthcare Company ASSOCIATION, USES AND THERAPEUTIC DIAGRAMS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP4233846B1 (en) * 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
MA46563B1 (fr) * 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103491948A (zh) * 2010-11-19 2014-01-01 吉里德科学公司 包含利匹韦林hci和富马酸替诺福韦酯的治疗组合物
CN107921003A (zh) * 2015-06-30 2018-04-17 吉利德科学公司 药物制剂
WO2019003150A2 (en) * 2017-06-30 2019-01-03 Viiv Healthcare Company ASSOCIATION, USES AND THERAPEUTIC DIAGRAMS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOLA FALCON-NEYRA等: "Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients:A multicenter study" *
马培奇;: "美FDA批准第二种"三合一"抗艾滋病毒药物制剂Complera" *

Also Published As

Publication number Publication date
WO2021001568A1 (en) 2021-01-07
MA56449A (fr) 2022-05-11
MX2021015627A (es) 2022-04-25
JP2026097814A (ja) 2026-06-16
BR112021026916A2 (pt) 2022-05-10
CN114080223A (zh) 2022-02-22
CA3144307A1 (en) 2021-01-07
EP3993799A1 (en) 2022-05-11
JP2022538449A (ja) 2022-09-02
JP2022538338A (ja) 2022-09-01
MX2022000060A (es) 2022-04-18
JP2026097815A (ja) 2026-06-16
KR20220028048A (ko) 2022-03-08
US20220313693A1 (en) 2022-10-06
CA3144534A1 (en) 2021-01-07
KR20220028049A (ko) 2022-03-08
AU2020300818A1 (en) 2022-03-03
BR112021026739A2 (pt) 2022-04-26
EP3993800A1 (en) 2022-05-11
US20240139186A1 (en) 2024-05-02
PH12021553288A1 (en) 2022-08-01
US20210000823A1 (en) 2021-01-07
WO2021001508A1 (en) 2021-01-07
IL289457A (en) 2022-02-01
MA56453A (fr) 2022-05-11
JOP20210347A1 (ar) 2023-01-30
AU2020300033A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
TWI923545B (zh) 19-去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
Wharton et al. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial
Dinger et al. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
JP2024510436A (ja) 大うつ病性障害の処置のための19-ノルc3,3-2置換c21-n-ピラゾリルステロイド
CN114761019A (zh) 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
CN101252937A (zh) 治疗月经周期相关症状的组合物和方法
Wiegratz et al. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy
Van Puyenbroeck et al. The additional value of bioelectrical impedance analysis-derived muscle mass as a screening tool in geriatric assessment for fall prevention
CN121969374A (zh) 使用ly3871801治疗自身免疫性和炎症性疾病的剂量方案
Landman et al. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial
CN114080223A (zh) 用利匹韦林治疗儿科患者的hiv的方法
EP4037661A1 (en) Method for treating hiv with cabotegravir and rilpivirine
HK40069556A (en) Methods of treating hiv in pediatric patients with rilpivirine
HK40069822A (en) Methods of treating hiv in pediatric patients with rilpivirine
CA3144534C (en) Methods of treating hiv in pediatric patients with rilpivirine
Johnson et al. A systematic review of the use of atazanavir in women infected with HIV-1
Spagnuolo et al. Lenacapavir for the Treatment of Heavily Treatment-experienced People with Multi-class Resistant HIV.
Steele et al. Truvada® Recommended by FDA Committee for Pre-exposure Prophylaxis in High-Risk HIV-Negative Individuals
Philippe COPEDOL: a two-year observational study in pretreated HIV-1-infected patients switching to a dolutegravir-based regimen
Verna et al. 553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
Francisco Data Released from Startmrk Study of Isentress Versus Efavirenz
Bruce Understanding the impact of an HIV intervention package for adolescents
Stuart STIsim: a co-transmission model of gonorrhea, chlamydia, trichomoniasis, and HIV

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069556

Country of ref document: HK